CSBR
Champions Oncology, Inc.
CSBR trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over CSBR overall, supported by stronger fundamentals and stronger modeled upside.
CSBR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Strong |
CSBR's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CSBR PE Valuation
CSBR has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CSBR Forward outlook
There aren't enough analyst estimates for CSBR to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CSBR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.08 | -138% |
| Q2 2026 | -$0.08 | -124% |
| Q1 2026 | -$0.15 | -134% |
| Q4 2025 | $0.18 | +$0.24 |
| Q3 2025 | $0.21 | +$0.47 |
| Q2 2025 | $0.33 | +$0.87 |
| Q1 2025 | $0.44 | +$1.16 |
| Q4 2024 | -$0.06 | +$0.65 |
CSBR has swung to a loss: it lost $0.08 per share over the past year, after a profit the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CSBR on earnings quality, reporting a profit while its opponent remains loss making.
CSBR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $15.2M | +8.8% |
| Q2 2026 | $13.8M | +12% |
| Q1 2026 | $16.6M | -2.8% |
| Q4 2025 | $15M | +11% |
| Q3 2025 | $14M | -0.5% |
| Q2 2025 | $12.4M | -12% |
| Q1 2025 | $17M | +42% |
| Q4 2024 | $13.5M | +17% |
CSBR's revenue is growing: $15M last quarter, up 8.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.7% | +1.1 points |
| Q2 2026 | -3.8% | +13 points |
| Q1 2026 | -1.7% | -28 points |
| Q4 2025 | 1.2% | -4.2 points |
| Q3 2025 | -3.8% | -13 points |
| Q2 2025 | -16% | -14 points |
| Q1 2025 | 26% | +48 points |
| Q4 2024 | 5.4% | +22 points |
CSBR's operating margin was −2.7% last quarter, up 1.1 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CSBR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CSBR on profitability, with a higher operating margin.
CSBR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$547K | -199% |
| Q2 2026 | -$2.2M | -134% |
| Q1 2026 | -$1.4M | -407% |
| Q4 2025 | -$2M | -$1.6M |
| Q3 2025 | $554K | +78% |
| Q2 2025 | $6.6M | +$8.3M |
| Q1 2025 | $448K | +$1.5M |
| Q4 2024 | -$377K | -186% |
CSBR's free cash flow was −$6M over the past year, against $7M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CSBR on cash generation, producing positive trailing cash flow while its opponent burns cash.
CSBR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +65.2K shares |
| 1 year | +0.8% | +109K shares |
| 3 years | +2.9% | +391K shares |
| 5 years | +3.7% | +496K shares |
| Available history | +7.2% | +933K shares |
CSBR has 14M diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | $32,000 |
| Q3 2023 | $602,000 |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CSBR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CSBR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -15.0x | Net Cash |
| Q2 2026 | -22.6x | Net Cash |
| Q4 2025 | -2.3x | Net Cash |
| Q3 2025 | -2.4x | Net Cash |
| Q2 2025 | -1.6x | Net Cash |
| Q1 2025 | -0.4x | Net Cash |
| Q4 2024 | -3.3x | Net Cash |
| Q4 2022 | -5.2x | Net Cash |
CSBR has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CSBR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.5 | Neutral |
| Stochastic | 11.5 | Oversold |
CSBR's weekly RSI is 37 (neutral) and its Stochastic is 11 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CSBR PE vs Healthcare Sector
| Metric | CSBR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CSBR has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CSBR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.79 | 2.9% below |
| 20 week MA | $5.17 | 10% below |
| 50 week MA | $5.83 | 20% below |
| 100 week MA | $6.81 | 32% below |
| 200 week MA | $6.01 | 23% below |
CSBR is in a downtrend: it's below all five of its weekly moving averages, and 23% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CSBR on trend strength, trading above more of its moving averages.
CSBR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.71 | $11.2 | +45% |
| 2021 | $11.2 | $8.04 | -28% |
| 2022 | $8.04 | $4.48 | -44% |
| 2023 | $4.48 | $5.62 | +25% |
| 2024 | $5.62 | $8.35 | +49% |
| 2025 | $8.35 | $6.98 | -16% |
| 2026 YTD | $6.98 | $4.65 | -33% |
CSBR has finished lower in three of the last six years. It's down 33% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CSBR on returns for 2026, with the stronger performance.